BridgeMD
Tests treatment safety and results for Liver Cancer (Primary and Metastatic)
Official title Clinical Study on the Safety, Efficacy, and Exploration of Immune Mechanisms of a Combined Multimodal Tumor Therapy System for Hepatic Malignancies
ClinicalTrials.gov ID: NCT07459309
What this study is testing
- What it's testing
- Clinical Study on the Safety, Efficacy, and Exploration of Immune Mechanisms of a Combined Multimodal Tumor Therapy System for Hepatic Malignancies
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 to 80
You may be able to join if
- Age 18-80 years, regardless of gender;
- Histopathologically confirmed or clinically diagnosed hepatic malignancies, including primary liver cancer and metastatic liver cancer;
- Presence of an image-evaluable target lesion for ablation, with the maximum diameter of the target lesion being 3-5 cm;
- Patient is intolerant to or refuses surgical resection;
- ECOG performance status score ≤ 2, with an expected survival period of greater than 3 months.
You likely can't join if
- Liver function classified as Child-Pugh C, unimprovable with hepatoprotective therapy;
- Massive or diffuse hepatocellular carcinoma;
- Presence of vascular tumor thrombus or invasion of adjacent organs;
- History of esophageal (gastric fundus) variceal rupture and bleeding within 1 month prior to treatment;
- Uncorrectable coagulation dysfunction and severe hematological abnormalities, with a high risk of severe bleeding;
- Refractory massive ascites, cachexia;
See the full eligibility criteria
- Age 18-80 years, regardless of gender;
- Histopathologically confirmed or clinically diagnosed hepatic malignancies, including primary liver cancer and metastatic liver cancer;
- Presence of an image-evaluable target lesion for ablation, with the maximum diameter of the target lesion being 3-5 cm;
- Patient is intolerant to or refuses surgical resection;
- ECOG performance status score ≤ 2, with an expected survival period of greater than 3 months.
- Liver function classified as Child-Pugh C, unimprovable with hepatoprotective therapy;
- Massive or diffuse hepatocellular carcinoma;
- Presence of vascular tumor thrombus or invasion of adjacent organs;
- History of esophageal (gastric fundus) variceal rupture and bleeding within 1 month prior to treatment;
- Uncorrectable coagulation dysfunction and severe hematological abnormalities, with a high risk of severe bleeding;
- Refractory massive ascites, cachexia;
- Active infection, especially inflammatory conditions of the biliary system;
- Severe functional failure of major organs such as liver, kidney, heart, lung, and brain;
- Impaired consciousness, or inability to cooperate with treatment;
- Previous systemic treatments (e.g., chemotherapy) with an interval of less than 2 weeks and not having recovered from prior treatment: CTCAE 6.0 grade \>1 (except for alopecia);
- Any other factors deemed by the investigator to make the subject unsuitable for participation or to affect the subject's involvement in the study.
The study team makes the final eligibility decision.
Where it's taking place
- Shanghai, Shanghai Municipality, China
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years to 80 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Shanghai, Shanghai Municipality, China. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.